Figure S1B

A  Vehicle  

D  anti-VEGF dAb

B  Pazopanib 2mg/ml  

E  GW771806 2mg/ml

C  Pazopanib 5mg/ml  

F  GW771806 5mg/ml
Figure S1A Representative early phase FFA images for eyes treated with topical pazopanib or GW771806
Representative early phase fluorescein angiograms showing the same lesions at days 7 and 18 post-induction of CNV by diode laser. Eyes were treated with (A) vehicle, (B and C) topical pazopanib, (D) intravitreal anti-VEGF dAb, or (E and F) topical GW771806. Each image corresponds to respective image in figure 7.

Figure S1B Representative near infrared images for eyes treated with topical pazopanib or GW771806
Representative near infrared images made 7 days after laser photocoagulation and were used to locate laser lesions in fluorescein angiograms of eyes treated with topical pazopanib or GW771806. Eyes were treated with (A) vehicle, (B and C) topical pazopanib, (D) intravitreal anti-VEGF dAb, or (E and F) topical GW771806. Each image corresponds to respective image in figure 7 and S1A.